Company Overview and News

 
Trading ideas: MNRB, NTPM, KESM, Utusan Melayu

2018-09-24 thestar.com.my
KUALA LUMPUR: MNRB Holdings Bhd , NTPM Holdings Bhd , KESM Industries Bhd and Utusan Melayu (Malaysia) Bhd are among the stocks to watch on Monday, according to JF Apex Research.
5754 6459 5066 9334

 
KLCI to consolidate, immediate support at 1,800 points

2018-09-23 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI is expected to consolidate today with immediate support at 1,800 points.
5754 4863 5738 6459 UPBMF 5066 MYPRY MYTEF 5014 2089 9334

 
MAHB, United Plantations, Utusan, TM, Binasat, KESM, NTPM, Country Heights and MNRB

2018-09-21 theedgemarkets
KUALA LUMPUR (Sep 21): Based on corporate announcements and news flow today, stocks in focus for Monday (Sep 24) may include the following: Malaysia Airports Holdings Bhd, United Plantations Bhd, Utusan Melayu (Malaysia) Bhd, Telekom Malaysia Bhd, Binasat Communications Bhd, KESM Industries Bhd, NTPM Holdings Bhd, Country Heights Holdings Bhd and MNRB Holdings Bhd.
UPBMF 5066 5088 2089 5014 9334 5754 4863 5738 6459 MYPRY MYTEF 1902

 
MNRB defers repayment of RM320m credit facility

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): Reinsurer MNRB Holdings Bhd has extended the repayment date of an RM320 million credit facility it obtained from AmBank (M) Bhd by five months, from tomorrow to March 22, 2019.
6459 BSMAF 1818

 
MNRB retraces from 5-year low to rise 1.3% on AmanahRaya's underwriting pledge

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): MNRB Holdings Bhd’s shares climbed 1.29% this morning as AmanahRaya Trustees Bhd gave its undertaking in writing to subscribe in full its entitlement and those of undersubscribed excess rights shares under MNRB's proposed rights issue to raise about RM400 million.
6459

 
AmanahRaya gives undertaking to subscribe for MNRB rights shares

2018-09-13 theedgemarkets
KUALA LUMPUR: MNRB Holdings Bhd’s largest shareholder AmanahRaya Trustees Bhd has given its undertaking in writing to subscribe in full for its entitlement and also subscribe for undersubscribed excess rights shares under MNRB’s proposed rights issue to raise about RM400 million.
6459 BSMAF 1818

 
AmanahRaya Trustees to fully subscribe to MNRB rights shares

2018-09-12 thestar.com.my
The undertaking by AmanahRaya is subject to its subscription not requiring it to offer a mandatory general offer to the remaining entitled shareholders following takeover rules in Malaysia. The subscription by AmanahRaya must also not result in MNRB breaching the public spread requirement under the listing requirements, it said.
6459 BSMAF 1818

 
AmanahRaya gives undertaking to subscribe for MNRB rights shares

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): MNRB Holdings Bhd’s largest shareholder AmanahRaya Trustees Bhd has given its undertaking in writing to subscribe in full its entitlement and those of undersubscribed excess rights shares under MNRB's proposed rights issue to raise about RM400 million.
6459 BSMAF 1818

 
KLCI pares gains, remains up 0.44% as banks lift

2018-07-19 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI pared some its gains at the midday break today and was up 0.44%, against the backdrop of higher regional markets.
PBLOF MLYBY MLYNF 7113 TPGVF 1295 3794 5014 9334 0131 TGLVY 1155 4588 3867 8613 6459 5819 MYPRY 1929

 
KLCI rises 0.56% as banking heavyweights lift

2018-07-19 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI rose 0.56% at mid-morning today, boosted by gains including at index-linked banking heavyweights.
PBLOF 7251 MLYNF 1295 7153 3794 2089 5014 9334 3867 6459 CSX MS 7083 MLYBY UPBMF 0170 0131 7123 1155 4588 MYPRY

 
MNRB falls 8.12% on proposing rights issue to raise RM400m

2018-07-19 theedgemarkets
KUALA LUMPUR (July 19): Shares of reinsurer MNRB Holdings Bhd fell 8.12% in early trade this morning after it proposed to undertake a rights issue to raise gross proceeds of about RM400 million, which the issue price and entitlement basis would be finalised later.
6459

 
KLCI to trend higher, immediate hurdle at 1,755

2018-07-18 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI is expected to trend higher today, tracking the overnight gains at most global markets, with immediate hurdle at 1,755 points.
7073 0101 5062 6459 5272 5268 7200

 
Maxis, Seacera, Sapura Energy, MNRB, TMC Life Sciences, Ranhill, Hua Yang, Ikhmas Jaya, Menang Corp and Tek Seng

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (July 19) may include the following: Maxis Bhd, Seacera Group Bhd, Sapura Energy Bhd, MNRB Holdings Bhd, TMC Life Sciences Bhd, Ranhill Holdings Bhd, Hua Yang Bhd, Ikhmas Jaya Group Bhd, Menang Corp (M) Bhd and Tek Seng Holdings Bhd.
7073 0101 5062 6459 5272 BSMAF 5268 7200 1818

 
Serba Dinamik, Xian Leng, SCGM, Perdana Petroleum, TA Global, MNRB, China Automobile Parts and JMR

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): Based on the corporate announcements and news flow today, companies in focus on Thursday (July 5) may include: Serba Dinamik, Xian Leng, SCGM, Perdana Petroleum, TA Global, MNRB, China Automobile Parts and JMR.
4898 7108 6459 5229 7043 5158 BSMAF 7121 1818

 
Mohd Din Merican resigns as MNRB ED, but remains president, group CEO

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): MNRB Holdings Bhd president and group chief executive officer Mohd Din Merican has stepped down as non-independent executive director effective July 1.
6459

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...